![]() ![]() The mechanism of TA’s action in the reduction of hyperpigmentation of melasma has not been fully understood. TA has been used through transdermal delivery using microneedling, oral administration of 250 mg twice daily for 6 months, topical 5% TA, topical TA in liposome formulation, topical 2% TA emulsion, and intradermal microinjection or intravenous administration. Since then, it has been proven that administration of TA is useful in the treatment of melasma. Nijor in Japan found in 1979 that severity of melasma was significantly reduced after 2–3 weeks. Tranexamic acid (TA) is also known as trans-4-(aminomethyl) cyclohexanecarboxylic acid. The main treatment is based on removal of any possible pathological factors and the use of a sunscreen and hypopigmenting agent, in combination with others such as tretinoin, topical steroids, or superficial peeling agents. Treatment of melasma remains a great challenge as there is no proven treatment modality. Tranexamic acid versus topical mesolightening mixture using the dermaroller in the treatment of melisma. ![]() How to cite this URL: Aly AA, AbdElMaksoud RE, Ismail I. How to cite this article: Aly AA, AbdElMaksoud RE, Ismail I. Keywords: Dermaroller, Melanin Area and Severity Index score, melasma, mesolighten, tranexamic acid TA is superior to mesolightening, as well as cost-effective in the treatment of melasma. Similarly, the later (four to eight sessions) (upon comparing the second set with the first set of sessions) and overall reduction was higher on the left side compared with that on the right side however, these differences were not statistically significant in terms of MASI.Ĭonclusion TA and topical mesolightening mixture are individually effective in the treatment of melasma. Results The initial (pre-4) reduction of MASI (after the first four sessions) on the left side (TA treated) was significantly higher than that on the right side. ![]() This was followed by 3 months of follow-up. For each patient, the following was done after taking an informed consent: history taking, dermatological examination, Wood’s light examination, Melanin Area and Severity Index (MASI) score calculation, photography, physician’s global assessment by independent investigators, patient’s global evaluation, eight sessions of transdermal delivery of TA and topical mesolightening mixture, with a session every week (mixture of kojic acid 3%, TA 0.01%, azelaic acid 4% (19,20), L-ascorbic acid 1 g, and water for injection), and recording of the adverse effects every session. Patients and methods This split-face study was carried out on 15 patients having melasma. ![]() The use of Dermaroller may increase the effective delivery of active ingredients in topical mesolightening mixture and TA.Īim The aim of this split-face study was to compare the safety and efficacy of transdermal delivery of TA versus topical mesolightening mixture using the Dermaroller in the treatment of melasma. Background Use of localized microinjection of tranexamic acid (TA) has been studied for the treatment of melasma and was proved to be effective, but transdermal delivery of this agent has not been well studied. ![]()
0 Comments
Leave a Reply. |